Veradermics, Inc
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
MANE$148.44+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended March 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2026 | 2025 |
| Operating expenses: | ||
| Research and development | $20,925 | $11,447 |
| General and administrative | 8,937 | 1,468 |
| Total operating expenses | 29,862 | 12,915 |
| Loss from operations | (29,862) | (12,915) |
| Other income: | ||
| Interest income | 2,481 | 482 |
| Other income | 149 | 33 |
| Total other income, net | 2,630 | 515 |
| Loss before income taxes | (27,232) | (12,400) |
| Income tax benefit | — | — |
| Net loss | $(27,232) | $(12,400) |
| Net loss attributable to common stock | $(30,011) | $(14,582) |
| Net loss per share of common stock, basic and diluted | $(1.32) | $(19.79) |
| Weighted average common stock outstanding, basic and diluted | 22,704,124 | 736,933 |
| Other comprehensive loss: | ||
| Net unrealized losses on marketable securities | (584) | — |
| Total other comprehensive loss | (584) | — |
| Total comprehensive loss | $(27,816) | $(12,400) |
Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)
| Redeemable Convertible Preferred Stock · Stockholders' Equity (Deficit) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A RedeemableConvertible PreferredStock · Series B RedeemableConvertible PreferredStock · Series C RedeemableConvertible PreferredStock · Subscription Receivable · Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · TotalStockholders’ Equity(Deficit) | |||||||||||||||||||||
| (in thousands, except share amounts) · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount | |||||||||||||||||||||
| Balance, December 31, 2024 | 12,865,375 | $36,860 | 55,246,971 | $66,285 | — | $— | $(3,848) | 736,933 | $1 | $750 | $— | $(49,231) | $(48,480) | ||||||||
| Issuance of Series B Redeemable Convertible Preferred Stock, net of issuance costs of $10 | — | — | 6,998,834 | 8,423 | — | — | — | — | — | — | — | — | — | ||||||||
| Subscription receivable settled through research and development services received | — | — | — | — | — | — | 357 | — | — | — | — | — | — | ||||||||
| Stock-based compensation | — | — | — | — | — | — | — | — | — | 213 | — | — | 213 | ||||||||
| Net loss | — | — | — | — | — | — | — | — | — | — | — | (12,400) | (12,400) | ||||||||
| Balance, March 31, 2025 | 12,865,375 | $36,860 | 62,245,805 | $74,708 | — | $— | $(3,491) | 736,933 | $1 | $963 | $— | $(61,631) | $(60,667) | ||||||||
| Redeemable Convertible Preferred Stock · Stockholders' Equity (Deficit) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A RedeemableConvertible PreferredStock · Series B RedeemableConvertible PreferredStock · Series C RedeemableConvertible PreferredStock · Subscription Receivable · Common Stock · Additional Paid-In Capital · Subscription Receivable · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · TotalStockholders’ Equity(Deficit) | |||||||||||||||||||||||
| (in thousands, except share amounts) · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount | |||||||||||||||||||||||
| Balance, December 31, 2025 | 12,865,375 | $36,860 | 62,245,805 | $78,903 | 118,682,683 | $150,563 | $(1,849) | 749,760 | $1 | $2,346 | $— | $60 | $(123,421) | $(121,014) | |||||||||
| Issuance of common stock in connection with initial public offering, net of issuance costs of $25,666 | — | — | — | — | — | — | — | 17,339,294 | — | 269,102 | — | — | — | 269,102 | |||||||||
| Conversion of redeemable convertible preferred stock to common stock upon initial public offering | (12,865,375) | (36,860) | (62,245,805) | (78,903) | (118,682,683) | (150,563) | 1,849 | 19,250,410 | — | 266,326 | (1,849) | — | — | 264,477 | |||||||||
| Subscription receivable settled through research and development services received | — | — | — | — | — | — | — | — | — | — | 621 | — | — | 621 | |||||||||
| Stock-based compensation | — | — | — | — | — | — | — | — | — | 5,259 | — | — | — | 5,259 | |||||||||
| Stock option exercises | — | — | — | — | — | — | — | 826 | — | 11 | — | — | — | 11 | |||||||||
| Unrealized loss on marketable securities | — | — | — | — | — | — | — | — | — | — | — | (584) | — | (584) | |||||||||
| Net loss | — | — | — | — | — | — | — | — | — | — | — | — | (27,232) | (27,232) | |||||||||
| Balance, March 31, 2026 | — | $— | — | $— | — | $— | $— | 37,340,290 | $1 | $543,044 | $(1,228) | $(524) | $(150,653) | $390,640 | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.